|
|
|
Insider
Information: |
Atwood Brian G |
Relationship: |
Chief Executive Office... |
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
157,758 |
|
Indirect Shares
|
20,247,283 |
|
|
Direct
Value |
$491 |
|
|
Indirect Value
|
$42,677,459 |
|
|
Total
Shares |
20,405,041 |
|
|
Total
Value |
$42,677,950 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Welltek Incorporated |
WTKND |
Director |
2008-03-07 |
0 |
2005-02-23 |
0 |
Premium* |
|
Cadence Pharmaceuticals Inc |
CADX |
Director |
2006-10-30 |
0 |
2014-03-19 |
0 |
Premium* |
|
Helicos Biosciences Corp |
HLCSQ |
Director, 10% Owner |
2007-05-30 |
0 |
2009-09-18 |
10,709,818 |
Premium* |
|
Trius Therapeutics Inc |
TSRX |
Director, 10% Owner |
2010-08-06 |
0 |
2010-08-06 |
3,235,839 |
Premium* |
|
Clovis Oncology, Inc. |
CLVS |
Director |
2020-11-09 |
32,758 |
2020-11-09 |
127,432 |
Premium* |
|
Five Prime Therapeutics Inc |
FPRX |
Director |
2013-09-23 |
0 |
2013-09-23 |
1,092,152 |
Premium* |
|
Veracyte, Inc. |
VCYT |
Director, 10% Owner |
2013-11-04 |
0 |
2013-11-04 |
21,232 |
Premium* |
|
Immune Design Corp. |
IMDZ |
Director, 10% Owner |
2014-07-29 |
0 |
2014-07-29 |
2,208,210 |
Premium* |
|
Opgen Inc |
OPGN |
Director, 10% Owner |
|
0 |
2015-05-08 |
2,554,211 |
Premium* |
|
Atreca Inc |
BCEL |
Director |
|
0 |
2019-06-24 |
49,654 |
Premium* |
|
Phoenix Biotech Acquisition Corp. |
PBAX |
Chief Executive Office... |
2024-02-14 |
125,000 |
2024-02-14 |
248,735 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
50 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CLVS |
Clovis Oncology, Inc. |
Director |
|
2017-06-26 |
4 |
A |
$0.00 |
$0 |
I/I |
5,210 |
25,577 |
0 |
- |
|
BCEL |
Atreca Inc |
Director |
|
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
8,791 |
49,654 |
0 |
- |
|
PBAX |
Phoenix Biotech Acquisiti... |
Chief Executive Officer |
|
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
PBAX |
Phoenix Biotech Acquisiti... |
Chief Executive Officer |
|
2024-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
248,735 |
248,735 |
0 |
- |
|
CLVS |
Clovis Oncology, Inc. |
Director |
|
2019-08-20 |
4 |
OE |
$0.29 |
$7,500 |
D/D |
25,862 |
25,862 |
0 |
- |
|
HLCSQ |
Helicos Biosciences Corp |
Director |
|
2009-09-18 |
4 |
B |
$2.57 |
$625,013 |
I/I |
242,931 |
10,709,818 |
2.25 |
- |
|
CLVS |
Clovis Oncology, Inc. |
Director |
|
2020-11-09 |
4 |
OE |
$3.08 |
$21,240 |
D/D |
6,896 |
32,758 |
0 |
- |
|
TSRX |
Trius Therapeutics Inc |
Director |
|
2010-08-06 |
4 |
B |
$5.00 |
$4,572,645 |
I/I |
914,529 |
3,235,839 |
2.25 |
- |
|
CADX |
Cadence Pharmaceuticals I... |
Director |
|
2008-02-20 |
4 |
A |
$5.34 |
$6,999,998 |
I/I |
1,310,861 |
28,787 |
0 |
- |
|
OPGN |
Opgen Inc |
Director |
|
2015-05-08 |
4 |
B |
$6.00 |
$2,479,992 |
I/I |
413,332 |
485,925 |
2.25 |
- |
|
CADX |
Cadence Pharmaceuticals I... |
Director |
|
2009-02-18 |
4 |
A |
$7.13 |
$9,913,096 |
I/I |
1,390,336 |
8,704 |
0 |
- |
|
CADX |
Cadence Pharmaceuticals I... |
Director |
|
2014-02-12 |
4 |
OE |
$7.84 |
$5,450,117 |
I/I |
695,168 |
13,056 |
0 |
- |
|
HLCSQ |
Helicos Biosciences Corp |
Director |
|
2007-05-30 |
4 |
B |
$9.00 |
$999,999 |
I/I |
111,111 |
111,111 |
2.25 |
- |
|
IMDZ |
Immune Design Corp. |
Director |
|
2014-07-29 |
4 |
B |
$12.00 |
$2,799,996 |
I/I |
233,333 |
2,208,210 |
2.25 |
- |
|
IMDZ |
Immune Design Corp. |
Director |
|
2014-07-29 |
4 |
S |
$12.00 |
$2,500,008 |
I/I |
(208,334) |
1,974,877 |
0 |
- |
|
FPRX |
Five Prime Therapeutics I... |
Director |
|
2013-09-23 |
4 |
B |
$13.00 |
$999,999 |
I/I |
76,923 |
1,092,152 |
2.1 |
- |
|
CADX |
Cadence Pharmaceuticals I... |
Director |
|
2014-02-12 |
4 |
D |
$14.00 |
$5,450,130 |
I/I |
(389,295) |
10,618 |
0 |
- |
|
CADX |
Cadence Pharmaceuticals I... |
Director |
|
2014-03-19 |
4 |
D |
$14.00 |
$70,098,952 |
I/I |
(5,007,068) |
0 |
0 |
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-25 |
4 |
S |
$35.76 |
$2,274,717 |
I/I |
(63,100) |
975,094 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-25 |
4 |
S |
$36.52 |
$1,259,947 |
I/I |
(34,100) |
940,994 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-25 |
4 |
S |
$37.22 |
$104,544 |
I/I |
(2,800) |
938,194 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-24 |
4 |
S |
$37.95 |
$3,725,114 |
I/I |
(97,500) |
1,040,694 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-21 |
4 |
S |
$38.33 |
$3,264,214 |
I/I |
(84,300) |
1,203,894 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-24 |
4 |
S |
$38.65 |
$96,670 |
I/I |
(2,500) |
1,038,194 |
|
- |
|
WTKND |
Welltek Incorporated |
Director |
|
2004-05-21 |
4 |
S |
$39.06 |
$2,596,121 |
I/I |
(65,700) |
1,138,194 |
|
- |
|
50 Records found
|
|
Page 2 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|